These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36439640)

  • 1. Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.
    Bixio R; Adami G; Bertoldo E; Giollo A; Morciano A; Bertelle D; Orsolini G; Idolazzi L; Rossini M; Viapiana O
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221137125. PubMed ID: 36439640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of iloprost in systemic sclerosis in a real-life experience.
    Bellando-Randone S; Bruni C; Lepri G; Fiori G; Bartoli F; Conforti ML; Moggi-Pignone A; Guiducci S; Giuggioli D; Colaci M; Spinella A; Ferri C; Matucci-Cerinic M
    Clin Rheumatol; 2018 May; 37(5):1249-1255. PubMed ID: 29470737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review.
    Jamart C; Levesque H; Thietart S; Fain O; Rivière S; Benhamou Y; Mekinian A
    Front Med (Lausanne); 2022; 9():878970. PubMed ID: 35872796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens.
    Schioppo T; Scalone L; Cozzolino P; Mantovani L; Cesana G; De Lucia O; Murgo A; Ingegnoli F
    Reumatismo; 2019 Jul; 71(2):62-67. PubMed ID: 31309775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and persistence of intravenous iloprost in systemic sclerosis.
    Martins P; Dourado E; Fonseca JE; Romão V; Resende C
    ARP Rheumatol; 2022; 1(2):122-128. PubMed ID: 35810370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens.
    Barsotti S; Lorenzoni V; Di Battista M; d'Ascanio A; Silvia B; Puccetti L; Turchetti G; Della Rossa A; Mosca M
    Scand J Rheumatol; 2021 Jul; 50(4):307-313. PubMed ID: 33622195
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial.
    Schioppo T; Orenti A; Boracchi P; De Lucia O; Murgo A; Ingegnoli F
    Rheumatology (Oxford); 2018 Aug; 57(8):1408-1416. PubMed ID: 29733400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
    Cutolo M; Zampogna G; Vremis L; Smith V; Pizzorni C; Sulli A
    J Rheumatol; 2013 Jan; 40(1):40-5. PubMed ID: 23118114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study.
    Colaci M; Lumetti F; Giuggioli D; Guiducci S; Bellando-Randone S; Fiori G; Matucci-Cerinic M; Ferri C
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):179-183. PubMed ID: 28980901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iloprost infusion through elastomeric pump in the treatment of Raynaud's phenomenon and digital ulcers.
    Fartura Braga Temido MH; Gomes M; Parente F; Santos L
    J Scleroderma Relat Disord; 2019 Feb; 4(1):NP1-NP4. PubMed ID: 35382145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
    Caramaschi P; Martinelli N; Volpe A; Pieropan S; Tinazzi I; Patuzzo G; Mahamid H; Bambara LM; Biasi D
    Clin Rheumatol; 2009 Jul; 28(7):807-13. PubMed ID: 19301062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tolerability, safety and efficacy of Iloprost infusion without peristaltic pump in systemic sclerosis].
    Arreghini M; Prudente P; Maglione W; Arnoldi C; Tosi S; Marchesoni A
    Reumatismo; 2001; 53(2):140-144. PubMed ID: 12163888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a novel method of intravenous infusion of the prostaglandin analogue iloprost for the treatment of lower-limb critical ischemia: An open-label, nonrandomized study in two cohorts.
    Veroux P; Veroux M; Macarone M; Bonanno MG; Tumminelli MG
    Curr Ther Res Clin Exp; 2004 May; 65(3):255-65. PubMed ID: 24672081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
    Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
    Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.